Most trusted partner in therapeutic drug discovery with fully integrated services and cutting-edge platform technologies across multiple modalities
Empowering drug discovery and development through AI/ML-driven innovation and integrated solutions
We support partners and collaborators with AI-enabled discovery platforms, foundational technologies, and fully integrated wet and dry lab services. With expertise across multiple modalities, we confidently tackle challenging programs and deliver success backed by years of scientific and operational excellence.
Accelerating discovery with Alloy’s integrated AI/ML
Alloy Therapeutics embeds AI/ML directly into the core of our discovery and development platforms, uniting predictive modeling with a global wet-lab engine to drive real biological outcomes. Trained on one of the industry’s largest proprietary experimental datasets, our models shorten design cycles, improve prediction accuracy, and enable teams to rapidly move from concept to human data with speed, precision, and capital efficiency.
AI/ML powered end-to-end discovery services and proprietary platforms
We put AI/ML at the center of antibody and bispecific discovery —streamlining campaigns from design to IND. Our in vivo platforms, generative modeling, and in silico developability tools work together to rapidly produce high-quality, de-risked candidates ready for downstream development.
TCRm antibodies mimic the function of T-cell receptors by targeting intracellular peptides presented on cell surface MHC complexes (pMHC), opening up a wide range of intracellular targets in oncology and infectious disease. Keyway™ TCRm discovery is the first fully integrated platform and service, combining our world-class antibody discovery expertise with the pioneers of TCR therapeutics.
Empowering breakthroughs with Alloy’s antisense platform
Alloy Therapeutics integrates AI/ML with foundational antisense technologies to overcome the therapeutic index and delivery barriers that have historically limited ASO drug candidates. Collaborate with us to rapidly refine existing sequences or design de novo molecules in our Anticlastic™ format—a transiently cyclized structure engineered for improved potency, safety, and scalability.
Next-gen cell therapies designed for speed, safety, and scale
A versatile T cell platform delivers off-the-shelf cell therapies with enhanced safety, potency, and scalability. Engineered with γδTCRs, customizable CARs and armoring technologies, built on Alloy’s hypoimmune iPSC platform, it enables rapid innovation, reduces risks such as GvHD and host rejection, lowers manufacturing costs, and accelerates the clinical development of next-generation therapies.
Collaboration among scientists, competition against disease
We collaborate with our partners to leverage the full potential of our technology and services, acting as an innovation engine for the drug discovery industry.